- Home
- IRIX vs NRXS Comparison
IRIX vs NRXS Comparison
Compare IRIX & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRIX
- NRXS
- Stock Information
- Founded
- IRIX 1989
- NRXS 2011
- Country
- IRIX United States
- NRXS United States
- Employees
- IRIX N/A
- NRXS N/A
- Industry
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- NRXS
- Sector
- IRIX Health Care
- NRXS
- Exchange
- IRIX Nasdaq
- NRXS Nasdaq
- Market Cap
- IRIX 16.5M
- NRXS 13.0M
- IPO Year
- IRIX 1996
- NRXS 2023
- Fundamental
- Price
- IRIX $1.02
- NRXS $2.50
- Analyst Decision
- IRIX
- NRXS Strong Buy
- Analyst Count
- IRIX 0
- NRXS 1
- Target Price
- IRIX N/A
- NRXS $7.00
- AVG Volume (30 Days)
- IRIX 66.0K
- NRXS 102.0K
- Earning Date
- IRIX 08-07-2025
- NRXS 08-08-2025
- Dividend Yield
- IRIX N/A
- NRXS N/A
- EPS Growth
- IRIX N/A
- NRXS N/A
- EPS
- IRIX N/A
- NRXS N/A
- Revenue
- IRIX $48,804,000.00
- NRXS $2,934,945.00
- Revenue This Year
- IRIX $9.61
- NRXS $138,883.78
- Revenue Next Year
- IRIX N/A
- NRXS $118.59
- P/E Ratio
- IRIX N/A
- NRXS N/A
- Revenue Growth
- IRIX N/A
- NRXS 27.52
- 52 Week Low
- IRIX $0.78
- NRXS $1.33
- 52 Week High
- IRIX $2.27
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- IRIX 58.92
- NRXS 51.20
- Support Level
- IRIX $0.92
- NRXS $2.23
- Resistance Level
- IRIX $1.01
- NRXS $2.59
- Average True Range (ATR)
- IRIX 0.05
- NRXS 0.15
- MACD
- IRIX 0.02
- NRXS -0.00
- Stochastic Oscillator
- IRIX 81.08
- NRXS 56.73
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).